135280-144

Use of the GUARDANT360 noninvasive tumor sequencing assay on 300 patients across colorectal, melanoma, lung, breast, and prostate cancers and its clinical utility.

Category: 
Tumor Biology
Session Type and Session Title: 
This abstract will not be presented at the 2014 ASCO Annual Meeting but has been published in conjunction with the meeting.
Abstract Number: 
e22041
Citation: 
J Clin Oncol 32, 2014 (suppl; abstr e22041)
Author(s): 
AmirAli Talasaz, Stefanie Mortimer, Dragan Sebisanovic, LaiMun Siew, Aubrey Zapanta, Gangwu Mei, Ben Schiller, Helmy Eltoukhy; Guardant Health, Inc., Redwood City, CA

Abstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^).

Abstract Disclosures

Abstract: 

Background: Analysis of genomic alterations in advanced malignant disease is quickly becoming the standard of care in oncology. Biopsies are risky, often costly and may not capture genetic changes that can emerge over time or in response to therapy. In contrast, GUARDANT360, a blood-based liquid biopsy approach that analyzes circulating tumor DNA (ctDNA), offers a simple and comprehensive tool for real-time tumor genetic profiling in advanced refractory cancer patients. Methods: We studied the performance of GUARDANT360 in five prevalent cancers: colorectal, melanoma, lung, breast, and prostate. Over 500 plasma samples and 100 matched tumors from a total of 300 unique patients were analyzed using GUARDANT360, a single-molecule next-generation digital sequencing assay with ability to detect somatic mutations and copy number variations with exquisite sensitivity. The assay covers sequences across a total of 54 actionable genes covering approximately 80 kbps. Select patients were treated on the basis of ctDNA alterations detected by GUARDANT360. Results: The overall detection rate of somatic alterations in ctDNA approached 85% for all indications (the range of detectable ctDNA mutations was 0.03%-87%). The concordance of tumor mutations to GUARDANT360 ranged from 67% (blood draw > 6 months post biopsy) to 93% (concurrent blood draw at time of biopsy). The dominant genetic mutations observed were similar to those previously reported for solid tumors. About 60% of cases with colorectal, breast and lung cancers had actionable mutations. The select patients treated on the basis of observed ctDNA alterations exhibited significant positive clinical outcomes (PR) suggesting strong potential for clinical utility of ctDNA sequencing. Conclusions: Advances in single-molecule sequencing and bioinformatics make possible the ultra-sensitive detection of somatic mutation and amplifications. Comprehensive profiling of ctDNA shows reasonable concordance to tumor profiles and illustrates the potential to improve the care of advanced refractory cancer patients.